Side effects of rifampicin. A clinical study.
D000208:Acute Disease; D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000553:Ambulatory Care; D000681:Amylases / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury; D004342:Drug Hypersensitivity / Q000209:etiology*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects*; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013268:Stimulation, Chemical; D013307:Streptomycin / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D004977:Ethambutol; D011239:Prednisolone; D000637:Transaminases; D000681:Amylases; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin